Interv Akut Kardiol. 2004;3(2):98-99

SYNERGY STUDY - LOW-MOLECULAR-WEIGHT HEPARIN IN THE EARLY INVASIVE THERAPY OF ACUTE CORONARY SYNDROME

Petr Janský
Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze

SYNERGY study has proven that low-molecular-weight heparin enoxaparin is as effective as unfractionated heparin in patients with non-ST-segment elevation acute coronary syndrome treated by early invasive revascularization strategy.

Keywords: acute coronary syndrome, enoxaparin, early revascularization.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janský P. SYNERGY STUDY - LOW-MOLECULAR-WEIGHT HEPARIN IN THE EARLY INVASIVE THERAPY OF ACUTE CORONARY SYNDROME. Interv Akut Kardiol. 2004;3(2):98-99.

Studie SYNERGY prokázala, že nízkomolekulární heparin enoxaparin je přinejmenším stejně účinný jako nefrakcionovaný heparin u pacientů s akutním koronárním syndromem bez elevací ST segmentu léčených časnou invazivní revaskularizační strategií.

SYNERGY STUDY - LOW-MOLECULAR-WEIGHT HEPARIN IN THE EARLY INVASIVE THERAPY OF ACUTE CORONARY SYNDROME

SYNERGY study has proven that low-molecular-weight heparin enoxaparin is as effective as unfractionated heparin in patients with non-ST-segment elevation acute coronary syndrome treated by early invasive revascularization strategy.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-452. Go to original source... Go to PubMed...
    2. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-1601. Go to original source... Go to PubMed...
    3. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/ non-Q wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-1608. Go to original source... Go to PubMed...
    4. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238-244. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.